Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints

References

• Kohn EC, Lee JM, Ivy SP. The HRD decision-which PARP inhibitor to use for whom and when. Clin Cancer Res off J Am Assoc Cancer Res. 2017 Dec 1;23(23):7155–7157.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018 Dec 27; 379(26):2495–2505.
   PubMed Web of Science ®Google Scholar
• Dizon DS, Dupont J, Anderson S, et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol. 2003 Dec;91(3):584–590.
   PubMed Web of Science ®Google Scholar
• Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997 Jan;15(1):187–192.
   PubMed Web of Science ®Google Scholar
• Duska LR, Kohn EC. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol. 2017 Nov;28(suppl_8):viii8–viii12.
   PubMedGoogle Scholar
• Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996;12(3):333–337.
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71.
   PubMed Web of Science ®Google Scholar
• Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016 Apr;2(4):482–490.
   PubMed Web of Science ®Google Scholar
• https://www.thermofisher.com/us/en/home/clinical/preclinical-companion-diagnostic-development/oncomine-oncology/analytical-performance-oncomine-nci-match-trial-assay.html. Performance verification of Oncomine Assays and NCI-MATCH Trial Assay. cited 2018 Nov 27. Available from: https://www.thermofisher.com/us/en/home/clinical/preclinical-companion-diagnostic-development/oncomine-oncology/analytical-performance-oncomine-nci-match-trial-assay.html.
   Google Scholar
• Hovelson DH, McDaniel AS, Cani AK, et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015 Apr;17(4):385–399.
   PubMed Web of Science ®Google Scholar
• https://www.foundationmedicine.com/genomic-testing/foundation-one-cdx. FoundationOne CDx. cited 2018 Nov 27. Available from: https://www.foundationmedicine.com/genomic-testing/foundation-one-cdx.
   Google Scholar
• Moschetta M, George A, Kaye SB, et al. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016 Aug;27(8):1449–1455.
   PubMed Web of Science ®Google Scholar
• Available from:https://myriadmyriak.com/scientific-presentations.
   Google Scholar
• Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017 May 15;123(10):1721–1730.
   PubMed Web of Science ®Google Scholar
• https://myriad.com/products-services/precision-medicine/bracanalysis-cdx/.
   Google Scholar
• Yates M, Timms K, Daniels M, et al. Next generation sequencing of BRCA1/2 in high grade ovarian tumors expands BRCA defects beyond germline mutations. Race/Ethnicity. 2014;25:95.
   Google Scholar
• Norquist B, Brady MF, Harrell MI, et al. Mutations in homologous recombination genes and response to treatment in GOG 218: an NRG Oncology study. Gynecol Oncol. 2016;141:2.
   PubMedGoogle Scholar
• Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010 Aug 1;28(22):3570–3576.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Rustin G, Paul J, et al. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol. 2013 Mar;24(3):679–687.
   PubMed Web of Science ®Google Scholar
• Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12629–12633.
   PubMed Web of Science ®Google Scholar
• Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032–18037.
   PubMed Web of Science ®Google Scholar
• Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017 Jan;18(1):75–87.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al., investigators SOE-O. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep; 18(9):1274–1284.
   PubMed Web of Science ®Google Scholar
• Fabbro M, Moore KN, Dorum A, et al. Efficacy and safety of niraparib as maintenance treatment in older patients (>/=70years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecol Oncol. 2019 Jan 9.
   Web of Science ®Google Scholar
• Wang ZC, Birkbak NJ, Culhane AC, et al.,, . Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res off J Am Assoc Cancer Res. 2012 Oct 15;18(20):5806–5815.
   PubMed Web of Science ®Google Scholar
• Kaplan AR, Gueble SE, Liu Y, et al. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci Transl Med. 2019;11(492).
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302–1308.
   PubMed Web of Science ®Google Scholar
• Scanlon SE, Glazer PM. Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA Repair (Amst). 2015 Aug;32:180–189.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005 Apr 14; 434(7035):913–917.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul;15(8):852–861.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al., investigators A. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949–1961.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03330405. NCT03330405 Avelumab plus talazoparib in locally advanced or metastatic solid tumors. [ cited 2019 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03330405.
   Google Scholar
• Landrum LM, Brady WE, Armstrong DK, et al. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Feb;140(2):204–209.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02588105. NCT02588105 Study to assess the safety and preliminary efficacy of AZD1056 at increasing dose alone or in combination with other anticancer treatment in patients with advanced cancer. [ cited 2019 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02588105.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02595892. NCT02595892 Gemcitabine hydrochloride alone or with M6620 in treating patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. [ cited 2019 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02595892.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03462342. NCT03462342 Combination ATR and PARP inhibitor (CAPRI) trial with AZD6738 and olaparib in recurrent ovarian cancer. [ cited 2019 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03462342.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03872427. NCT03872427 Testing whether cancers with specific mutations respond better to glutaminase inhibitor CB839 HCL anticancer treatment, the BEGIN study. [ cited 2019 May 20]; Available from: https://clinicaltrials.gov/ct2/show/NCT03872427.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT01357161. NCT01357161 A study of MK1775 in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for participants with platinum-sensitive ovarian tumors with the p53 gene mutation (MK1775-004). [ cited 2019 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01357161.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02797964. NCT02797964 A phase 1/2 trial of SRA737 in subjects with advanced cancer. [ cited 2019 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02797964.
   Google Scholar
• Infante JR, Hollebecque A, Postel-Vinay S, et al. Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. Clin Cancer Res off J Am Assoc Cancer Res. 2017 May 15;23(10):2423–2432.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02465060. NCT02465060 Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma (the MATCH screening trial). [ cited 2019 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02465060.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02465060. NCT02657928 Ribociclib and letrozole in treating patients with relapsed ER positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer. [ cited 2019 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02657928.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT035316458. NCT035316458 Fulvestrant plus abemaciclib in women with advnaced low grade serous carcinoma. [ cited 2019 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT035316458.
   Google Scholar
• Shapiro GI, Do KT, Tolaney SM, et al. Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors. Cancer Res. 2017;77(13Supplement):CT047–CT47.
   Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct;15(11):1207–1214.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374–3382.
   PubMed Web of Science ®Google Scholar
• Lin ZP, Ratner ES, Whicker ME, et al. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Mol Cancer Res. 2014 Mar;12(3):381–393.
   PubMed Web of Science ®Google Scholar
• Lin ZP, Zhu YL, Lo YC, et al. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. PLoS One. 2018;13(11):e0207399.
   PubMed Web of Science ®Google Scholar
• Ratner ES, Zhu YL, Penketh PG, et al. Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair. Br J Cancer. 2016 Mar 29;114(7):777–786.
   PubMed Web of Science ®Google Scholar
• Stone RL, Beavis AL, Baras A, et al. Cell cycle biomarker discovery for phase 0 clinical trials in type II endometrial cancer. Gynecol Oncol. 2018;149:118.
   Google Scholar
• Kunos C, Radivoyevitch T, Abdul-Karim FW, et al. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study. J Transl Med. 2012 Apr;27(10):79.
   Google Scholar
• Kunos CA, Radivoyevitch T, Ingalls ST, et al. Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia. Future Oncol. 2012 Feb;8(2):145–150.
   PubMed Web of Science ®Google Scholar
• Kunos CA, Radivoyevitch T, Waggoner S, et al. Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol. 2013 Jul;130(1):75–80.
   PubMed Web of Science ®Google Scholar
• Harnor SJ, Brennan A, Cano C. Targeting DNA-dependent protein kinase for cancer therapy. ChemMedChem. 2017 Jun 21;12(12):895–900.
   PubMed Web of Science ®Google Scholar
• Pike KG, Barlaam B, Cadogan E, et al. The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one). J Med Chem. 2018 May 10;61(9):3823–3841.
   PubMed Web of Science ®Google Scholar
• Blackford AN, Jackson SPATM. ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Mol Cell. 2017 Jun 15; 66(6):801–817.
   PubMed Web of Science ®Google Scholar
• Foote KM, Nissink JWM, McGuire T, et al. Discovery and Characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. J Med Chem. 2018 Nov 21;61(22):9889–9907.
   PubMed Web of Science ®Google Scholar
• Do K, Wilsker D, Ji J, et al. Phase I study of single-agent AZD1775 (MK-1775), a wee1 kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol. 2015 Oct 20;33(30):3409–3415.
   PubMed Web of Science ®Google Scholar
• Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009 Nov;8(11):2992–3000.
   PubMed Web of Science ®Google Scholar
• Rajeshkumar NV, De Oliveira E, Ottenhof N, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res off J Am Assoc Cancer Res. 2011 May 1;17(9):2799–2806.
   PubMed Web of Science ®Google Scholar
• Leijen S, van Geel RM, Sonke GS, et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with tp53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016 Dec 20;34(36):4354–4361.
   PubMed Web of Science ®Google Scholar
• Parsels LA, Parsels JD, Tanska DM, et al. The contribution of DNA replication stress marked by high-intensity, pan-nuclear gammaH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors. Cell Cycle. 2018;17(9):1076–1086.
   PubMed Web of Science ®Google Scholar
• Karnak D, Engelke CG, Parsels LA, et al. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2014 Oct 1;20(19):5085–5096.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Cabanero M, Cristea MC, et al. A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia. J Clin Oncol. 2019;37(15_suppl):5518.
   Web of Science ®Google Scholar
• Brill E, Yokoyama T, Nair J, et al. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer. Oncotarget. 2017 Dec 19;8(67):111026–111040.
   PubMedGoogle Scholar
• Lee JM, Nair J, Zimmer A, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol. 2018 Feb;19(2):207–215.
   PubMed Web of Science ®Google Scholar
• Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 May 28;521(7553):489–494.
   PubMed Web of Science ®Google Scholar
• Etemadmoghadam D, Weir BA, Au-Yeung G, et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19489–19494.
   PubMed Web of Science ®Google Scholar
• Gross MI, Demo SD, Dennison JB, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890–901.
   PubMed Web of Science ®Google Scholar
• Alkan HF, Walter KE, Luengo A, et al. Cytosolic aspartate availability determines cell survival when glutamine is limiting. Cell Metab. 2018 Nov 6;28(5):706–20 e6.
   PubMed Web of Science ®Google Scholar
• Momcilovic M, Bailey ST, Lee JT, et al. Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer. Cell Rep. 2017 Jan 17;18(3):601–610.
   PubMed Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 Apr 1;30(4):551–557.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039–2045.
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484–2496.
   PubMed Web of Science ®Google Scholar